Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
Regeneron is deepening its foothold in Japan’s oncology market, adding over 50 sales reps this summer as it looks to capitalize on the expanded use of Libtayo (cemiplimab) and build on the country’s role as a priority market for future…
To read the full story
Related Article
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
BUSINESS
- Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
- Shionogi, Torii File Lotion Form of Corectim in Japan
March 2, 2026
- Arcalis Completes mRNA Drug Facility, Establishes End-to-End CDMO Platform
March 2, 2026
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…